An interim analysis recommended ending the trial.
OBEcure Ltd. has suspended the clinical trial of its anti-obesity drug, Histalean, on the basis of a recommendation by an interim analysis found no statistically significant results. The company decided to examine the findings and reassess the assumptions of the trial.
The Histalean trial was conducted on 30 patients taking Zyprexa, an anti-psychotic drug. The interim analysis was conducted by an independent outside board.
OBEcure is a portfolio company of Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT), an incubator company.
Published by Globes [online], Israel business news - www.globes-online.com - on October 22, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008